From the cancer point of view, UCHL3 is an attractive “druggable” target and previous efforts focused on developing UCHL3 inhibitors that specifically target UCHL3 in plasmodium falciparum parasite, offering promising selectivity due to structural differences compared to human UCHL3 (Artavanis-Tsakonas et al., 2010). The gene discussed is UCHL3; the disease is cancer.